This content is from: Features
What’s behind the drug patent furore in South Africa
South Africa’s draft IP policy has generated a lot of negative publicity. But, as David Cochrane explains, further consultation is hoped for and any amendments to the Patent Act are some way off
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here